REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|November 2, 2021
Daily OTC Pearl: Metamucil
Author(s)Saro Arakelians, PharmD
Metamucil increases the bulk of stool, an effect that helps to cause movement of the intestines.
Advertisement
OTC/Lifestyle Pearl of the Day: Metamucil
Indication: Metamucil is used to treat
Insight:
- Metamucil increases the bulk of stool, an effect that helps to cause movement of the
intestines . - It also works by increasing the amount of water in the stool, making it softer and easier to pass.
- Directions: To prevent choking from this medication, take it with a full glass of water or other liquid (8 ounces/240 milliliters).
- If taking the wafers, chew them thoroughly before swallowing. Mix in a full glass of water or other liquid (8 ounces/240 milliliters), stir completely, and drink right away. More liquid may be added to the mixture if it becomes too thick.
- Caution: This product may decrease the absorption of other
medications patients may be taking. Take this product at least 2 hours from other medications. Patients should consult a physician or pharmacist for more information or with any questions. - It may take 1 to 3 days before this medication starts working. Use this medication regularly to get the most benefit from it.
Sources:
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5